Patents by Inventor Scott M. Duncan

Scott M. Duncan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2
    Publication number: 20240140990
    Abstract: Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.
    Type: Application
    Filed: August 8, 2023
    Publication date: May 2, 2024
    Inventor: Scott M. Duncan
  • Capsaicinoid prodrug compounds and their use in treating medical conditions
    Patent number: 11820727
    Abstract: The invention provides capsaicinoid prodrug compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as pain, and in agonizing TRPV1 activity.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: November 21, 2023
    Assignee: Centrexion Therapeutics Corporation
    Inventors: James N. Campbell, Scott M. Duncan
  • Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH
    Patent number: 11773136
    Abstract: Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: October 3, 2023
    Assignee: Stealth BioTherapeutics Inc.
    Inventor: Scott M. Duncan
  • CRYSTALLINE SALT FORMS
    Publication number: 20230279049
    Abstract: Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: December 2, 2022
    Publication date: September 7, 2023
    Inventors: Scott M. Duncan, Martin P. Redmon
  • CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE
    Publication number: 20230203093
    Abstract: Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH2 and Boc-D-Arg-DMT. The crystalline forms may be used in the synthesis of elamipretide.
    Type: Application
    Filed: December 21, 2022
    Publication date: June 29, 2023
    Inventors: Scott M. Duncan, Martin P. Redmon
  • Crystalline dipeptides useful in the synthesis of elamipretide
    Patent number: 11560404
    Abstract: Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH2 and Boc-D-Arg-DMT. The crystalline forms may be used in the synthesis of elamipretide.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: January 24, 2023
    Assignee: Stealth BioTherapeutics Inc.
    Inventors: Scott M. Duncan, Martin P. Redmon
  • Crystalline salt forms
    Patent number: 11555053
    Abstract: Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: January 17, 2023
    Assignee: Stealth BioTherapeutics Inc.
    Inventors: Scott M. Duncan, Martin P. Redmon
  • Capsaicinoid prodrug compounds and their use in treating medical conditions
    Patent number: 11447444
    Abstract: The invention provides capsaicinoid prodrug compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as pain, and in agonizing TRPV1 activity.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: September 20, 2022
    Assignee: Centrexion Therapeutics Corporation
    Inventors: James N. Campbell, Scott M. Duncan
  • Crystalline salt forms of SBT-20
    Patent number: 11325943
    Abstract: Disclosed are various crystalline salt forms of L-Phe-D-Arg-L-Phe-L-Lys-NH2.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 10, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: Scott M. Duncan
  • Crystalline bis- and tris-hydrochloride salt of elamipretide
    Patent number: 11261213
    Abstract: Disclosed are crystalline forms of the bis- and tris-(hydrochloride) salts of D-Arg-Tyr(2,6-DiMe)-Lys-Phe-NH2, which is also known as MTP-131.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: March 1, 2022
    Assignee: Stealth BioTherapeutics Inc.
    Inventor: Scott M. Duncan
  • Capsaicinoid prodrug compounds and their use in treating medical conditions
    Patent number: 11254659
    Abstract: The invention provides capsaicinoid prodrug compounds (e.g., prodrugs of resiniferatoxin, tinyatoxin, iodoresiniferatoxin, and related compounds), pharmaceutical compositions, and their use in the treatment of medical conditions, such as pain, and in agonizing TRPV1 activity.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 22, 2022
    Assignee: Centrexion Therapeutics Corporation
    Inventors: James N. Campbell, Scott M. Duncan
  • CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2
    Publication number: 20210292362
    Abstract: Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.
    Type: Application
    Filed: April 8, 2021
    Publication date: September 23, 2021
    Inventor: Scott M. Duncan
  • CRYSTALLINE SALT FORMS OF SBT-20
    Publication number: 20210292361
    Abstract: Disclosed are various crystalline salt forms of L-Phe-D-Arg-L-Phe-L-Lys-NH2.
    Type: Application
    Filed: June 1, 2018
    Publication date: September 23, 2021
    Inventor: Scott M. Duncan
  • CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE
    Publication number: 20210292274
    Abstract: Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH2 and Boc-D-Arg-DMT.
    Type: Application
    Filed: April 7, 2021
    Publication date: September 23, 2021
    Inventors: Scott M. Duncan, Martin P. Redmon
  • Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH
    Patent number: 11034724
    Abstract: Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: June 15, 2021
    Assignee: Stealth BioTherapeutics Corp.
    Inventor: Scott M. Duncan
  • Crystalline dipeptides useful in the synthesis of elamipretide
    Patent number: 10975118
    Abstract: Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH2 and Boc-D-Arg-DMT.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: April 13, 2021
    Assignee: Stealth BioTherapeutics Corp.
    Inventors: Scott M. Duncan, Martin P. Redmon
  • N-carboxyanhydride-based-scale synthesis of elamipretide
    Patent number: 10961273
    Abstract: Disclosed are methods of making elamipretide (MTP-131), a peptide compound with therapeutic potential for treating various mitochondrial myopathies. The synthesis of the peptide can be achieved via the use of N-carboxyanhydride-modified amino acid residues, which increases the efficiency of the synthetic process and the purity of the peptide product generated.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: March 30, 2021
    Assignee: Stealth Biotherapeutics Corp.
    Inventors: Scott M. Duncan, Jan Oudenes, Marc W. Andersen
  • CRYSTALLINE BIS- AND TRIS-HYDROCHLORIDE SALT OF ELAMIPRETIDE
    Publication number: 20210061853
    Abstract: Disclosed are crystalline forms of the bis- and tris-(hydrochloride) salts of D-Arg-Tyr(2,6-DiMe)-Lys-Phe-NH2, which is also known as MTP-131.
    Type: Application
    Filed: May 4, 2020
    Publication date: March 4, 2021
    Inventor: Scott M. Duncan
  • CRYSTALLINE SALT FORMS
    Publication number: 20210047368
    Abstract: Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: May 4, 2020
    Publication date: February 18, 2021
    Inventors: Scott M. Duncan, Martin P. Redmon
  • Headlamp
    Patent number: D1017851
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: March 12, 2024
    Assignee: PACCAR Inc
    Inventors: Scott M. Conway, Steven H. Hovind, Jonathan S. Duncan, Ales Brostík, Roman Kopecký